Merck Stock Surges 8.82% on Positive mRNA Cancer Vaccine Trial Results

Key Facts

In a move reflecting the rapid evolution of the healthcare sector, Merck & Co shares recorded a significant jump driven by promising clinical data. The company's stock opened up 8.82% on August 19 following the announcement of positive results from the Phase 3 INTerpath-001 trial. These trials demonstrated the success of the individualized mRNA-based cancer vaccine, developed in collaboration with Moderna, when combined with Keytruda for treating melanoma patients.

This clinical breakthrough mitigates long-term investor concerns regarding the upcoming patent expiration of Keytruda, leading management to raise full-year revenue guidance. Per market data, the Pharmaceuticals & Medical Research sector rose by 2.19%, with peers showing mixed movement; the 0QAH.L instrument closed at 144.66 GBP and 6MK.DE at 125.04 EUR as of August 19, 2026, reflecting broader sector optimism fueled by new innovations.

Technically, MRK stock stood at $135.18 at the close of August 18, 2026, as investors monitor the sustainability of this upward momentum following the recent results. Looking at the economic calendar, there are no direct upcoming events for the pharmaceutical sector in the next seven days; however, markets are watching US Initial Jobless Claims on August 13 as a general indicator of macroeconomic health and its impact on liquidity flows into mega-cap stocks.